Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
Engineered virus expressing foreign antigens converts cold pancreatic tumors into hot immunotherapy-responsive cancers in preclinical models.
Oncolytic rVMG virus engineered to express donor alloantigens converts immune-cold pancreatic cancer (which is notoriously resistant to immunotherapy) into an immunologically active state, achieving TME remodeling and synergistic survival benefit with checkpoint inhibitors in two mouse PDAC models. The alloantigen mismatch strategy exploits transplant rejection mechanisms to create tumor immunogenicity without requiring existing neoantigens.
What the study was
- Study design
- Preclinical in vitro and in vivo (immunocompetent mouse) study
- Population
- Immunocompetent PDAC mouse models; in vitro PDAC cell lines
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal for ImmunoTherapy of Cancer
Why it surfaced
Novel alloantigen-expressing oncolytic virus strategy for immune-cold PDAC. Score capped per non-human model rule (≤5). Conceptually innovative but preclinical only. JITC publication adds credibility.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.